此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Phase I Safety and Feasibility Study of Intracoronary Delivery of Autologous Bone Marrow Derived Mononuclear Cells

2021年5月12日 更新者:Timothy J Nelson, MD, PhD

Phase I Safety and Feasibility Study of Intracoronary Delivery of Autologous Bone Marrow Derived Mononuclear Cells for Systemic, Single Right Ventricular Failure Due to Congenital Heart Disease

The objective of this study is to determine the safety and feasibility of autologous mononuclear cells (MNC) collected from bone marrow (BM) and intracoronary delivery for individuals with declining performance of their single right ventricle systemic pumps. This procedure has the potential to foster a new strategy for congenital heart patients. This is an open-label study of autologous MNC derived from bone marrow with a 2-year follow-up to document 1) related serious adverse events and 2) monitor changes in cardiac structure and function.

研究概览

详细说明

This study is an open label Phase I trial to determine the safety and feasibility of bone marrow-derived mononuclear cells delivered into the coronary circulation of subjects with Fontan circulation and right ventricular dysfunction. Subjects will be screened at outpatient clinic visits at Mayo Clinic and interested qualified subjects will be consented and offered participation in this trial. Once informed consent has been obtained; preoperative values will be established and a selection committee will review subjects within three days prior to planned procedure to confirm inclusion and exclusion criteria. This will require a non-study cardiologist to review the clinical case and confirm the baseline cardiac function with evidence of disease progression with right ventricle dysfunction. However, individuals with decreased cardiac function requiring inotropic support and immediate listing for cardiac transplantation will NOT be included such that the risk of this research procedure may not be acceptable. Following cell-based product delivery, subjects will be followed for 6-months according to a pre-determined schedule that includes imaging studies along with questionnaires, electrophysiology and laboratory studies. Subjects will be contacted for an additional 18-months for surveillance by phone.

研究类型

介入性

注册 (实际的)

10

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Minnesota
      • Rochester、Minnesota、美国、55905
        • Mayo Clinic

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

2年 至 30年 (孩子、成人)

接受健康志愿者

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Individuals with Fontan circulation with right ventricular dysfunction
  • Ejection fraction equal to or less than 40% despite optimal outpatient medical management for at least 3 months
  • Able to undergo bone marrow aspirate according to clinical consultation with hematology (INR must be maintained at or below 1.5)
  • Able to undergo an MRI or CT examination

Exclusion Criteria:

  • Individuals or parents of minors unwilling to consent to participation
  • Individuals with severe chronic diseases, extra-cardiac syndromes, or cancer
  • Females 10 years and older with positive pregnancy test or lack of effective birth control method
  • Individuals currently requiring IV inotropes
  • Individuals with bleeding disorders or history of thrombosis
  • Individuals not eligible for MRI and have elevated serum creatinine level (eGFR less that 45 mL/min) and therefore cannot have a CT examination
  • Individuals not eligible for MRI and have a prior significant reaction to intravenous contrast required for CT examination
  • Individuals with the following conditions within 60 days prior to procedure:

    • Cardiogenic shock or extracorporeal circulation;
    • New arrhythmia that required medication for control;
    • Documented infection requiring treatment with antibiotics, and/or current infection being treated with antibiotics;
    • Cardiac condition requiring emergency procedure;
    • Cardiovascular surgery;
    • Seizures or history of significant neurological injury;
    • Multi-system organ failure including acute or chronic renal failure

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Single-arm
Intracoronary delivery of autologous bone marrow-derived mononuclear cells using catheterization procedure
其他名称:
  • 跨国公司

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Number of related serious adverse events
大体时间:6 months post cell delivery
6 months post cell delivery

次要结果测量

结果测量
大体时间
Number of subjects who died
大体时间:6 months post cell delivery
6 months post cell delivery
Number of subjects with sustained or symptomatic ventricular arrhythmias
大体时间:6 months post cell delivery
6 months post cell delivery
Number of subjects with acute decompensated heart failure
大体时间:6 months post cell delivery
6 months post cell delivery
Number of subjects with myocardial infarction
大体时间:6 months post cell delivery
6 months post cell delivery
Number of subjects with cardiac infection
大体时间:6 months post cell delivery
6 months post cell delivery
Number of subjects with unexpected cardiovascular procedures within 6 months following cellular transplantation
大体时间:6 months post cell delivery
6 months post cell delivery
Percentage of subjects that have cells delivered
大体时间:6 months post cell delivery
6 months post cell delivery
Percentage of subjects completing the 6-month follow-up
大体时间:6 months post cell delivery
6 months post cell delivery
Change in CT/MRI derived right ventricle ejection fraction
大体时间:Baseline, 6 months post cell delivery
Baseline, 6 months post cell delivery
Change in diastolic ventricular volume
大体时间:Baseline, 6 months post cell delivery
Baseline, 6 months post cell delivery
Change in systolic ventricular volume
大体时间:Baseline, 6 months post cell delivery
Baseline, 6 months post cell delivery
Change in echocardiography derived right ventricle ejection fraction
大体时间:Baseline, 6 months post cell delivery
Baseline, 6 months post cell delivery

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

合作者

调查人员

  • 首席研究员:Muhammad Y Qureshi, MBBS、Mayo Clinic
  • 研究主任:Timothy J Nelson, M.D., Ph.D.、Mayo Clinic

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2015年8月1日

初级完成 (实际的)

2020年11月1日

研究完成 (实际的)

2020年11月1日

研究注册日期

首次提交

2015年9月10日

首先提交符合 QC 标准的

2015年9月11日

首次发布 (估计)

2015年9月15日

研究记录更新

最后更新发布 (实际的)

2021年5月14日

上次提交的符合 QC 标准的更新

2021年5月12日

最后验证

2021年5月1日

更多信息

与本研究相关的术语

其他研究编号

  • 13-006427

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

3
订阅